Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 3993 - 4000 of 11616 results
Federal Trade Commission and Justice Department Release Joint Antitrust Guidance for COVID-19 Public Health Efforts
March 25, 2020| Blog| Viewpoint
CMS Offers Unprecedented Flexibility in Medicare Enrollment Requirements in Light of the COVID-19 Pandemic
March 25, 2020| Blog| Viewpoint
First-Ever CCPA Cause of Action Filed in a Federal Court, but Is This Class Claim Short-Lived?
March 25, 2020| Blog| Viewpoint
2nd Circuit Affirms 5Pointz Whitewashing Violated Visual Artists Rights Act
March 25, 2020| Blog| Viewpoint
Federal Circuit Denies En Banc Rehearing of Panel Decision in Arthrex, Which Held PTAB Appointments Were Unconstitutional
March 25, 2020| Blog| Viewpoint
Governor of Massachusetts Orders Closure of All Non-Essential Businesses: What Office Landlords Should Know
March 25, 2020| Blog| Viewpoint
Public Safety and Fraud During the COVID-19 Outbreak: Will Congress Take Action?
March 25, 2020| Blog| Viewpoint
COVID-19 Fraud Alerts and Government Actions
March 24, 2020| Blog| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.